Lipoprotein(a) management after Lp(a)HORIZON trial
I saw news that a new Lp(a)-lowering drug trial (Pelacarsen, the Lp(a)HORIZON study) successfully lowered Lp(a) but did NOT reduce heart attacks, strokes, or cardiovascular death. Does this mean lowering Lp(a) doesn't actually help, and what should someone with high Lp(a) do now?
This was an important test of the long-standing "Lp(a) hypothesis." In the Phase 3 Lp(a)HORIZON trial (more than 8,000 high-risk patients), pelacarsen successfully lowered Lp(a), but did not significantly reduce major cardiovascular events (heart attack, stroke, or cardiovascular death) compared with placebo. Genetic and epidemiologic evidence still strongly supports high Lp(a) as a causal cardiovascular risk factor — this trial did not disprove that, it just did not show that lowering it with this particular drug reduces risk. It does not mean Lp(a)-lowering can never work: other agents, including olpasiran and lepodisiran, lower Lp(a) by roughly 90% or more, and their cardiovascular-outcomes trials are still ongoing and important to watch. For now, if your Lp(a) is high, treat it as a risk-enhancing factor and aggressively manage the modifiable risks you do control, particularly LDL cholesterol — current guidelines specifically support more intensive LDL-lowering when Lp(a) is elevated. Bottom line: if your Lp(a) is high, as a South Asian you should discuss this with your doctor and continue to advocate for aggressively lowering your LDL cholesterol, to a range in the 50s.